Anti-il5 nanoantibody and use thereof
AssigneeShanghai Novamab Biopharmaceuticals Co., Ltd.
InventorsYakun WAN, Min ZHU, Junwei GAI, Guanghui LI, Xiaoning SHEN
Life of this patent
Estimating the term…
Loading patent…
AssigneeShanghai Novamab Biopharmaceuticals Co., Ltd.
InventorsYakun WAN, Min ZHU, Junwei GAI, Guanghui LI, Xiaoning SHEN
Estimating the term…
An anti-IL5 nanoantibody, and a coding sequence for coding the anti-IL5 nanoantibody, a corresponding expression vector, a host cell capable of expressing the anti-IL5 nanoantibody, and a method for producing the anti-IL5 nanoantibody are provided. The nanoantibody can specifically recognize IL5 from humans and cynomolgus monkeys, does not recognize IL5 from mice, and has a good binding activity. The nanoantibody has a good IL5/IL5R blocking activity. The blocking activity is obviously superior to that of a control antibody Nucala. The nanoantibody can effectively inhibit the proliferation of TF-1 cells induced by IL5, and the inhibition activity thereof is superior to that of the control antibody Nucala. The expression yield of the nanoantibody in Pichia pastoris can reach 13 g/L, and the purity of target protein expressed in the supernatant is high.
An anti-IL5 nanobody, which can specifically bind to ILS, and the complementary determination region (CDR) of the VHH chain in the nanobody is one or more selected from the group consisting of:
(canceled)
Dependencies are inferred from the claim text.